Last reviewed · How we verify
Flu Vaccine (Year 3)
Flu Vaccine (Year 3) is a vaccine Biologic drug developed by The Jackson Laboratory. It is currently FDA-approved for Prevention of seasonal influenza in adults and children. Also known as: Flublok Quadrivalent.
The flu vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in that year's formulation.
The flu vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in that year's formulation. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | Flu Vaccine (Year 3) |
|---|---|
| Also known as | Flublok Quadrivalent |
| Sponsor | The Jackson Laboratory |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This prepares the immune system to recognize and rapidly neutralize circulating influenza viruses, reducing infection risk and severity. The specific strains included vary annually based on epidemiological predictions.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fever
- Fatigue
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flu Vaccine (Year 3) CI brief — competitive landscape report
- Flu Vaccine (Year 3) updates RSS · CI watch RSS
- The Jackson Laboratory portfolio CI
Frequently asked questions about Flu Vaccine (Year 3)
What is Flu Vaccine (Year 3)?
How does Flu Vaccine (Year 3) work?
What is Flu Vaccine (Year 3) used for?
Who makes Flu Vaccine (Year 3)?
Is Flu Vaccine (Year 3) also known as anything else?
What drug class is Flu Vaccine (Year 3) in?
What development phase is Flu Vaccine (Year 3) in?
What are the side effects of Flu Vaccine (Year 3)?
Related
- Drug class: All vaccine drugs
- Manufacturer: The Jackson Laboratory — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza in adults and children
- Also known as: Flublok Quadrivalent
- Compare: Flu Vaccine (Year 3) vs similar drugs
- Pricing: Flu Vaccine (Year 3) cost, discount & access